CML is a hematologic neoplasm sustained by the constitutive activation of the BCR::ABL1 fusion kinase that can successfully be targeted with TKIs, so that most CML patients nowadays obtain durable remissions. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.